The diabetes and weight-loss injection semaglutide can reduce asthma attacks by up to 40%, according to research presented at the European Respiratory Society (ERS) Congress in Barcelona, Spain. The study was led by Chloe Bloom, clinical associate professor in respiratory epidemiology at the National Heart & Lung Institute, Imperial College London, UK, and presented by Dr. Bohee Lee.
Semaglutide Reduces Asthma Attacks by Nearly 40%, Study Shows
Research presented at the European Respiratory Society Congress indicates that semaglutide, a diabetes and weight-loss injection, can reduce asthma attacks by nearly 40%. The study was led by Chloe Bloom from Imperial College London and presented by Dr. Bohee Lee. This finding could have implications for healthcare strategies in Iran, particularly in managing respiratory diseases.
👥 Key Players
📰 What Happened
A study presented at the European Respiratory Society Congress found that semaglutide, a drug typically used for diabetes and weight loss, can reduce asthma attacks by nearly 40%. This discovery could lead to new treatment options for asthma patients.
- Semaglutide is primarily known for treating diabetes and aiding weight loss.
- The study was conducted by researchers at Imperial College London.
💡 Why It Matters
📚 Background
Asthma is a significant health issue worldwide, and existing treatments may not be effective for all patients. Semaglutide's new application could provide a breakthrough.
🏷️ Entities Mentioned
Translated from the original and edited for English readers. View original source →
Translation confidence: 100%